Blackstone enters its October 16 earnings date carrying its sharpest one-month decline in recent memory, with options traders piling into puts and insider sales accelerating even as short sellers quietly retreat.
The price move is the starting point for everything else this week. BX closed at $114.00, down 8.1% over the past week and nearly 20% over the past month. That kind of drawdown in a large-cap alternative asset manager is not routine noise. The stock has given back the entire post-Q2 rally and then some, erasing gains that followed a strong July 23 earnings print, when BX jumped nearly 6% on the day and held most of it over the following week.
Options positioning reflects the anxiety. The put/call ratio has climbed to 1.65, above its 20-day average of 1.55 and running noticeably higher than it was through August, when the ratio was routinely printing below 1.40. The reading is not at an extreme on its own terms: the 52-week high is 1.87 and the z-score is less than one standard deviation above the mean. But the directional drift is clear. Traders have been adding put protection consistently since mid-September, a week-long accumulation rather than a one-day spike. With earnings 16 days out, the bias toward downside hedging is building steadily rather than arriving all at once.
Short interest, by contrast, tells a much calmer story. Bears have been reducing exposure throughout September. SI has fallen 8.3% over the past week to 2.55% of the free float, and is down more than 21% over the past month, from around 3.3% at the end of August to just over 19 million shares now. Borrow is essentially free at 0.39%, and availability is extraordinarily loose at over 2,195%, meaning there are roughly 22 shares available to borrow for every one currently shorted. The lending market carries no meaningful signal here. Shorts are not pressing the trade into weakness; if anything they have been covering into it.
The Street's picture is similarly divided. Analysts were broadly constructive after the Q2 beat, with Goldman Sachs raising its target to $127, RBC to $169, and Oppenheimer lifting to $140 on July 24 before raising again to $171 in August. Yet the consensus has stayed at hold, with ten analysts there against four at outperform and no buys at the bellwether houses. Goldman's Neutral at $127 is almost exactly where the stock is now, which means the firm with the most cautious post-earnings call effectively called the price. The bear case is well-articulated: BX's earnings power depends on realization timing, capital-markets conditions, and fee conversions that can slip if rate-sensitive assets reprice further or if the IPO window stays narrow. Bulls counter with the $1.35 trillion AUM base, record wealth-channel flows of $324 billion, and management's stated confidence in double-digit base fee growth into 2027. EPS surprise ranks in the 80th percentile of the ORTEX universe and analyst recommendation divergence sits in the 91st, reflecting genuine disagreement rather than a consensus drift one way.
The insider picture adds a layer worth noting. Director Joseph Baratta sold $12.4 million in BX shares on September 18, in two tranches at prices around $123 to $124, with no 10b5-1 plan on file. Those were discretionary sales at prices well above where the stock now trades. Earlier in August, the Chief Legal Officer and Chief Accounting Officer also sold, at prices in the $145 to $147 range. The 90-day net across all insiders is minus $24.4 million. Director Ruth Porat made small purchases in August totalling around $62,000, but they do not come close to offsetting the selling pressure from senior management. None of these transactions appear to be plan-driven, which makes the cluster more meaningful than routine compensation-related disposals.
Wikipedia attention for BX has jumped to a z-score of 1.9 against its own 90-day history, the highest retail-attention reading in the recent period. That is colour rather than signal: there is no measured alt-data lead for BX against its reported figures, but the spike in page views coincides with a stock that has lost a fifth of its value in a month and is two weeks from its next earnings print. Retail attention at elevated levels ahead of a major catalyst is worth tracking even when causality cannot be established.
What to watch is straightforward: the Q2 print on July 23 produced a 6% single-day gain that the stock has entirely reversed. Whether the October 16 result carries a comparable reaction, or whether the 20% pre-earnings drawdown has already priced in disappointment on realizations and fee conversions, is the question the positioning leaves unresolved.
See the live data behind this article on ORTEX.
Open BX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
